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Antilipopolysaccharide (anti-LPS) immunoglobulin G (IgG) and IgM have been associated with protection
from LPS effects in vivo. We investigated the presence of IgE and anti-LPS in 32 patients that had experienced
severe traumatic injury and in 35 healthy volunteers; we also investigated whether IgE anti-LPS was associated
with important clinical events. Plasma samples were collected daily from patients in the intensive care unit and
on one occasion from volunteers; the samples were assayed for IgE anti-LPS. IgE anti-LPS was assayed by
enzyme-linked immunosorbent assay with monoclonal anti-human IgE as the capture antibody. Detection was
accomplished with biotin-labeled LPS (Escherichia coli J5 mutant) followed by streptavidin-peroxidase with
2,2'-azino(3-ethylbenzthiazoline)sulfonic acid as the substrate. The assay was demonstrated to be specific for
IgE and LPS-biotin by nonreactivity of control sera with high-titer anti-LPS IgG and IgM and by inhibition
with unlabeled LPS. IgE anti-LPS was detected in 1 of 35 healthy controls (2.9%o) and 25 of 32 traumatically
injured patients (78%) (P < 0.001). The presence of IgE anti-LPS was associated with a lower incidence of
death (P = 0.026) and of renal failure (P = 0.0012). There was no apparent temporal relationship between
detection of IgE anti-LPS and clinical events. IgG anti-LPS was detected more frequently in patients that were
positive for IgE anti-LPS (P = 0.06) but was not associated with clinical events. The inability to detect IgE
anti-LPS may be related to adverse clinical events through depletion of specific IgE due to LPS exposure after
trauma or through saturation of the assay by IgE with other specificities. We have reported increased total IgE
concentrations in these patients (J. T. DiPiro, R. G. Hamilton, T. R. Howdieshell, N. F. Adkinson, and A. R.
Mansberger, Ann. Surg. 215:460-466, 1992).
Lipopolysaccharide (LPS) is a component of the cell mem-
brane of gram-negative bacteria and is responsible for initiat-
ing the inflammatory events of gram-negative sepsis. LPS binds
to LPS-binding protein, producing stimulation of macrophages
and subsequent release of inflammatory mediators (such as
tumor necrosis factor alpha, interleukin-1, and interleukin-6).
This activation of inflammatory mediators initiates the physi-
ologic changes characteristic of the sepsis syndrome, with
continued activation leading to septic shock and multiple
organ failure (10).
There are a number of mechanisms in immunocompetent
hosts which modulate the response to LPS. The endogenous
interleukin-1 receptor antagonist directly antagonizes the in-
terleukin-1 proinflammatory effect. Potentially, binding of LPS
to LPS-binding protein can be controlled through downregu-
lation of LPS-binding-protein availability. Also, expression of
the LPS receptor on macrophages (CD14) could be downregu-
lated. The outcome following LPS exposure depends to a
certain extent on the presence of endogenous antibody that is
reactive with LPS. Endogenous anti-LPS immunoglobulin G
(IgG) and IgM antibodies have been associated with protec-
tion from endotoxin effects in vivo (5, 7, 12). Other isotypes of
anti-LPS antibody, including IgE, have not been studied.
We previously reported that total plasma IgE concentrations
are elevated following major traumatic injury and sepsis (2).
* Corresponding author. Mailing address: FI-1087 Medical College
of Georgia, Augusta, GA 30912. Phone: (706) 721-4915. Fax: (706)
721-3994. Electronic mail address: jdipiro@zeus.mcg.edu.
Detection of IgE anti-LPS may indicate that allergic mecha-
nisms are involved in the response to endotoxin. Classically,
this would involve activation of basophils and mast cells.
However, additional mechanisms may be involved, specifically,
an LPS effect through the activation of cells having low-affinity
IgE receptors (e.g., monocytes, eosinophils, platelets, and B
lymphocytes). Alternatively, elevated IgE concentrations may
be a marker for altered cytokine production after traumatic
injury.
Therefore, we attempted to determine if IgE anti-LPS could
be detected in the plasma of patients following major trau-
matic injury and if the presence of IgE anti-LPS was associated
with important clinical events such as sepsis, adult respiratory
distress syndrome, renal failure, and death.
MATERIALS AND METHODS
Clinical material. Prior to initiation of the study, banked
sera from a panel of 270 subjects known to have high total
serum IgE levels in the atopic range (>200 ng/ml as deter-
mined by the IMx [Abbott Diagnostics, North Chicago, Ill.])
were screened for the presence of IgE anti-LPS. This group
was used for selection of positive reference sera. Histories and
demographic data for these subjects were not available. All IgE
anti-LPS-positive sera identified in the screening assay were
confirmed by soluble-antibody inhibition in a second analysis
as described below. Plasma or serum samples were then
obtained from two groups of study subjects. Group 1 consisted
of 32 subjects who sustained major traumatic injury and were
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admitted to the trauma intensive care unit. This group con-
sisted of 29 males and 3 females with a mean age of 33 + 8
years. All patients had an American College of Surgeons
Hospital Trauma Index of 10 or greater (mean, 13.9 + 2.9;
range, 10 to 22), indicating a high degree of injury severity and
risk of mortality (1). A substantial percentage of these patients
developed sepsis (56%), respiratory distress syndrome (63%),
or renal failure (34%), and eight patients died during their
hospitalization (25%). These patients were selected from a
group of 72 trauma patients previously studied (8a). They
included all 18 patients of the 72-patient group who experi-
enced a septic event and 14 patients who stayed for similar
lengths of time in the trauma intensive care unit but who did
not experience a septic event. Plasma samples were obtained
daily from these patients while they were in the intensive care
unit. Group 2 consisted of 35 healthy volunteers who were
hospital employees. This group consisted of 16 males and 19
females with an average age of 31 ± 8.7 years. Allergy histories
were not available for either group. All subjects provided
written informed consent for blood collections.
Reagents. All chemicals, unless otherwise specified, were
obtained from Sigma Chemical Company, St. Louis, Mo. All
buffers were prepared with endotoxin-free deionized water.
LPS-biotin conjugate was prepared as follows. One milligram
of LPS (E. coli J5 rough mutant [catalog no. 301; List
Biological, Campbell, Calif.]) was added to 1 ml of phosphate-
buffered saline (PBS), pH 7.4, containing 4 [L of triethylamine
(T-0886; Sigma), and the mixture was gently vortexed. Sodium
m-periodate (2.1 mg; S-1878, Sigma) was added, and the
mixture was mixed gently for 20 min at room temperature. One
microliter of anhydrous glycerol (2136-01; J. T. Baker, Phil-
lipsburg, N.J.) was then added, and the mixture was vortexed.
After completion of this reaction, 5.6 mg of crystalline, biotin-
epsilon aminocaproyl hydrazide (Calbiochem Corporation, La
Jolla, Calif.) was dissolved in 263 ,ul of dimethyl sulfoxide
(Fisher Scientific, Fair Lawn, N.J.) in a separate glass tube by
vortexing. Then, 0.1 ml of the dimethyl sulfoxide-biotin-
hydrazide mixture was added to the tube containing LPS-
periodate. The mixture was rotated at room temperature for 2
h. Initially, LPS-biotin was dialyzed against PBS with a 2,000-
molecular-weight membrane (200 ml for 2 h, repeated three
times). This, however, did not improve the performance of the
product, and dialysis was deleted from the procedure. LPS-
biotin was stored at 4°C and prepared fresh each week.
Chromatographically purified human IgE-specific murine
monoclonal antibody (HP 6061) obtained from Hybridoma
Reagent Laboratory, Baltimore, Md., was used at 2 ,ug/ml in
PBS (13). Monoclonal anti-LPS core-lipid A (clone J18-8D2)
and the LPS 0 chain of E. coli O111:B4 (clone 042E1) (11)
were kindly provided by Martin Evans and Matthew Pollack
(Uniformed Services University, Bethesda, Md.). Commercial
intravenous IgG (Sandoglobulin; Sandoz Pharmaceuticals,
East Hanover, N.J.) was used in the specificity analysis de-
scribed below. Three high-titer serum samples containing IgG
and IgM anti-LPSs were selected by using a previously re-
ported enzyme immunoassay (4).
IgE, IgG, and IgM anti-LPS enzyme immunoassays. The
assay for anti-LPS-specific IgE was performed as follows.
Microtiter plates (Immunol 4 Removawell; Dynatech, Chan-
tilly, Va.) were coated for 1 h at room temperature and
overnight at 4°C with monoclonal anti-human IgE (HP 6061;
0.1 ml per well) that had been diluted with PBS (without
protein) to a final concentration of 10 ,ug/ml. The plates were
then washed five times with PBS-0.05% Tween 20 (PBS-T)
and blocked for 1 h at room temperature with PBS-0.5%
bovine serum albumin (Cohn Fraction V; A-7906; Sigma)
(PBS-BSA). Reference, positive control, and test sera diluted
1:2 to 1:20 in PBS-BSA were pipetted into duplicate wells (0.1
ml per well) and incubated for 2 h at room temperature. The
plates were washed four times with PBS-T, and 0.1 ml of
biotinylated LPS was added per well at 1 ,ug/ml in PBS-BSA.
Following a 2-h incubation at room temperature, the plates
were again washed four times, and streptavidin-horseradish
peroxidase (S-5512; Sigma) was added at 0.1 ml per well (1
jig/ml in PBS-BSA) for 1 h at room temperature. After a final
wash with PBS-T, 0.1 ml of 2,2'-azino(3-ethylbenzthiazoline)-
sulfonic acid (ABTS) (55 mg/100 ml in citrate-phosphate
buffer; A-1888; Sigma) was added. Color development was
stopped after 16 h with 2 mM sodium azide (S-2202; Sigma),
and the A410 was read with a microtiter plate reader (model
450; Bio-Rad, Rockville Center, N.Y.).
The immunoreactivity of the biotinylated LPS was tested
with two murine monoclonal antiendotoxin antibodies. Mi-
crowell plates were coated with 0.1 ml, diluted 1:1,000, of
either J18-8D2, an antibody with specificity for the core and
lipid A regions of LPS, or 042E1, an antibody with specificity
for the 0 chain of E. coli O111:B4 (11). Each plate was
incubated for 1 h at room temperature and overnight at 4°C.
After being washed with PBS-T, each plate was blocked with
0.2 ml of 0.5% BSA for 1 h and then rewashed. Biotinylated
LPS in 0.5% BSA was added in various dilutions. The detec-
tion system consisted of streptavidin-peroxidase (S-5512; Sig-
ma), which was added at 1 pLg/ml (0.1 ml per well) for 1 h; this
was followed by washing. ABTS as described above was then
added, and the reaction was stopped with sodium azide at 15
min. The A410 was determined.
IgG and IgM anti-LPS were tested by using an enzyme
immunoassay similar to that previously reported by Freuden-
berg et al. (4). Briefly, microwell plates (Immunol 4 Re-
movawell; Dynatech) were coated with LPS from E. coli (J5
mutant) at 12.5 ,ug/ml. After the plates were blocked with
PBS-BSA and washed, sera (diluted 1:16 to 1:128 in PBS) were
added and incubated for 1 h at room temperature. After
further washing, biotinylated mouse monoclonal anti-human
IgG (HP 6017B) or anti-human IgM (HP 6081B; Hybridoma
Reagent Laboratory) was added at 1 ,ug/ml in PBS-BSA. The
detection system consisted of streptavidin-peroxidase followed
by ABTS as described above.
Controls and determinations of IgE assay specificity. The
isotype specificity of the IgE anti-LPS assay was evaluated by
using patient sera that we had previously determined, using the
enzyme immunoassay described above, to contain IgG and
IgM anti-LPS with end-point titers of at least 1:128. In
addition, a commercial, purified IgG preparation (Sando-
globulin; Sandoz Pharmaceuticals) was tested. This IgG prep-
aration was used at a 1:100 dilution in 0.5% BSA, while the
sera were used at a 1:16 dilution.
A competitive inhibition test using nonbiotinylated LPS was
performed to determine LPS specificity. For this test, micro-
well plates were coated with murine monoclonal anti-human
IgE (Fc) (HP 6061) as described above and then blocked with
0.5% BSA for 1 h. Serum determined to be highly reactive with
IgE anti-LPS (from patient C-8097) by the assay described
here was then added at a 1:8 dilution in 0.5% BSA to 12 wells.
After incubation at room temperature for 2 h the plates were
washed. Then, 0.1 ml of nonbiotinylated LPS (E. coli JS
mutant) was added to duplicate wells in the following concen-
trations: 1 mg/ml, 0.1 mg/ml, 10 Fig/ml, 1 ,ug/ml, and 100 ng/ml.
PBS alone (100 ,ul) was added to the final two wells, and the
plates were kept at room temperature for 1 h. After the plates
were washed, biotinylated LPS was added; this was followed by
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FIG. 1. Dilutions of proposed positive control serum which had
IgE anti-LPS reactivity (from patient C-8097) and a negative control
serum (from patient D-1283) by using the IgE anti-LPS assay (±
standard deviation). Nonspecific binding is 0.210 absorbance units.
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FIG. 2. Immunoreactivity of biotinylated LPS (from the J5 E. coli
mutant, which does not possess an 0 side chain) with two murine
monoclonal, anti-LPS antibodies. J18-8D2 is known to be reactive with
the core and lipid A regions, while 042E1 is known to react only with
the 0 side chain of E. coli 0111:B4.
the addition of streptavidin-peroxidase and then ABTS as
detailed above. The A410 was determined.
Total IgE determination. Total serum IgE was measured by
an automated microparticle enzyme immunoassay (IMx; Ab-
bott Diagnostics). The lower limit of detection of the assay is
0.1 ng/ml. Specificity was confirmed by using purified IgE, IgM,
and IgG and albumin preparations. Further details for total
IgE determinations and results were previously published (2).
Clinical data. A complete clinical data base was maintained
for all trauma patients. This included the American College of
Surgeons Hospital Trauma Index, physiologic parameters, a
panel of chemistry and hematology laboratory tests, and
notation of major hospital events and operations. Definitions
used for sepsis syndrome, adult respiratory distress syndrome,
and renal failure have been previously published (2).
Statistics. The t test was used to compare means between
groups. The chi-square test was used for categorical variables.
A P value of less than or equal to 0.05 was accepted as
significant. Since the assay for IgE anti-LPS was qualitative but
not quantitative, results were classified on the basis of antibody
being detectable or nondetectable. Samples were considered positive
if the absorbance value for the sample was at least twice that of
negative serum control, with a P value (t test) of -0.001.
RESULTS
Assay validation. A dilution curve for the most highly
reactive patient serum (from patient C-8097) is shown in Fig.
1. This serum was used as a positive control for all further
assays of IgE anti-LPS and was included on each assay plate.
The coefficient of variation for replicates at a 1:16 dilution was
between 2.5 and 10% (mean, 6.6% ± 3.0%; n = 8). Figure 2
illustrates the immunoreactivity of the biotinylated LPS with
two murine anti-LPS antibodies. As shown, the conjugate was
reactive with the antibody known to have specificity for the
LPS core and lipid A regions (J18-8D2). There was minimal
reactivity with the 0-chain-specific antibody. This is as expected since
the LPS used to prepare the biotin conjugate was from the J5
mutant, which does not have an 0 chain on the LPS.
The specificity of the assay for IgE and for LPS was
demonstrated by three studies. In the first, sera that were
determined to be reactive with IgG and IgM anti-LPSs (titers
of at least 1:128) showed no reactivity in the assay system. Also,
the commercially available, purified IgG preparation (San-
doglobulin) was nonreactive. In the second study, the immu-
noreactivity of an IgE anti-LPS-positive test serum (C-8097)
was found to be completely inhibited by 100 ng of nonbiotiny-
lated LPS per ml. Finally, sera from patients determined to
have high total serum IgE levels (some greater than 10,000
ng/ml) were nonreactive in the assay system (data not shown).
Clinical samples. IgE anti-LPS was detected in 3 of the 270
nontrauma subjects with elevated total IgE levels (1.1%), 1 of
the 35 healthy control subjects (2.9%), and 25 of the 32
traumatically injured patients (78%) (P < 0.001). Titers ranged
from 1:2 to 1:128. In approximately 50% of the traumatically
injured patients with detectable IgE anti-LPS, antibody was
detected within 48 h of admission to the hospital (12 of 25
patients) and was detectable in samples collected from two
patients in the emergency room. The relationships of IgE
anti-LPS detection to clinical events and the presence of IgG
and IgM anti-LPS are shown in Table 1. The presence of IgE
anti-LPS was associated with lower incidences of death and
renal failure. The incidence of sepsis was lower in those
patients that were IgE anti-LPS positive, but this was not
significant (P = 0.075). IgE anti-LPS detection was not asso-
ciated with the development of adult respiratory distress
syndrome or related to splenectomy. There was no apparent
temporal relationship between the detection of IgE anti-LPS
and the occurrence of clinical events such as sepsis, adult
respiratory distress syndrome, renal failure, and death.
IgG and IgM anti-LPSs were detected in 59 and 53% of the
trauma patients, respectively. IgG anti-LPS was not associated
with any of the selected clinical features, with the exception of
a higher frequency of detectable IgG anti-LPS in patients
TABLE 1. Association of IgE anti-LPS with clinical events
No. (%) of patients
Clinical event experiencing event P value
or feature IgE anti-LPS IgE anti-LPS
positive (n = 25) negative (n = 7)
Sepsis 12 (48) 6 (86) 0.075
ARDSa 15 (60) 5 (71) 0.580
Renal failure 5 (20) 6 (86) 0.0012
Splenectomy 7 (28) 2 (29) 0.980
Death 4 (16) 4 (57) 0.026
Positive anti-LPS result
IgG 17 (68) 2 (29) 0.060
IgM 14 (56) 3 (43) 0.540
a Adult respiratory distress syndrome.
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following splenectomy (89 versus 48%; P = 0.033). IgM
anti-LPS was not associated with selected clinical events with
the exception of mortality. Seven of eight patients that died did
not have detectable IgM anti-LPS during their intensive care
unit stay (P = 0.0078). We have previously reported that these
patients had relatively low total IgM concentrations (2). Also,
patients that were positive for IgE anti-LPS were more likely to
be positive for IgG anti-LPS (68 versus 29%), but this was not
significant (P = 0.06).
Total IgE was measured in plasma samples collected on
admission to the emergency room and then collected weekly
while the patient remained in the intensive care unit. Although
total IgE concentrations increased in most patients during
recovery, there was no apparent association between the
concentration of total IgE in plasma and the detection of IgE
anti-LPS (P = 0.56). Finally, there was no association between
the detection of IgE anti-LPS and the American College of
Surgeons Hospital Trauma Index.
DISCUSSION
This is the first known report describing the existence of
LPS-specific IgE. The detection of this antibody suggests one
additional mechanism for immune system activation by LPS.
IgE specific for LPS may be involved in the activation of
basophils, mast cells, and Langerhans' cells through binding of
high-affinity receptors and in the activation of macrophages,
platelets, and B lymphocytes through binding of low-affinity
receptors.
LPS-reactive IgE was detected in the sera of a substantial
majority of patients following traumatic injury (78%) and in
the serum of only 1 of 35 healthy subjects (2.9%). In the
injured patients, the absence of detectable IgE anti-LPS was
associated with higher frequencies of renal failure and death.
The 32 trauma patients selected for this study were among the
most severely injured of approximately 3,600 patients admitted
to the trauma service during the study period. The severity of
injury is substantiated by the high percentage of patients
experiencing organ dysfunction and death.
We have reported (2) that the same trauma patient group
had elevated total plasma IgE concentrations compared with
healthy volunteer controls and with patients following elective
abdominal surgery. Within the injured group, total IgE con-
centrations were significantly higher in patients that developed
sepsis syndrome than in those that did not. Given the relatively
low titers of IgE anti-LPS and the high concentrations of total
IgE in plasma (greater than 200 ng/ml), most of the IgE
produced in this condition is not LPS specific. The current
finding that IgE anti-LPS is associated with lower frequencies
of organ failure, sepsis, and death appears inconsistent with the
findings for total IgE. One explanation for the findings for total
IgE and IgE anti-LPS is that the traumatic injury and sepsis
syndrome cause altered cytokine regulation which results in
increased IgE production. A number of findings for trauma-
tized and septic patients suggest that increased IgE production
may be favored. Substances that enhance IgE production, e.g.,
interleukin-6 and prostaglandin E2, are reported to be in-
creased after trauma and sepsis (3, 6, 9). Also, an inhibitor of
interleukin-4-induced IgE production, gamma interferon, is
decreased (8). Production of IgE anti-LPS, which may be
present in undetectable amounts in most healthy individuals,
may be increased with nonspecific IgE upregulation after
trauma. However, a portion of injured patients may be exposed
to LPS in amounts great enough to deplete IgE anti-LPS.
Therefore, since LPS exposure may result in organ failure and
death, depleted IgE anti-LPS may be associated with these
adverse events. Certainly, further studies must be conducted to
confirm this hypothesis. An alternative explanation is that
upregulation of nonspecific IgE production after injury may
result in saturation of the assay, inhibiting detection of IgE
anti-LPS.
From this study and our previously published data, it
appears that IgE production is upregulated after traumatic
injury and sepsis. IgE may serve either as a mechanism for cell
activation or as a marker of cytokine disregulation following
traumatic injury. It is possible, but we believe unlikely, that IgE
anti-LPS is protective. Detection of IgE anti-LPS in selected
trauma patients is an important finding in that depletion of IgE
anti-LPS from plasma may indicate substantial LPS exposure
with subsequent mediator release; this exposure increases the
risk of organ failure and death. Whether the absence of IgE
anti-LPS in injured patients is a better predictor of morbidity
and mortality than direct measurement of LPS or of cytokines
(such as interleukin-1, interleukin-6, or tumor necrosis factor
alpha) remains to be determined.
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